Mark Tepper, president of CytRx subsidiary CytRx Laboratories, is scheduled to speak at the Strategic Research Institute’s Metabolic Diseases Drug Discovery World Summit next month.
The conference is scheduled for July 26-27 in San Diego, Calif.
Tepper is slated to discuss the development of small molecule and RNAi-based therapeutics for obesity and type II diabetes.
Executive recruitment firm McCooe & Associates said this week that Tom Ittelson has been selected as executive director of technology management for the University of Massachusetts Medical School.
The executive director position was left vacant last year with the departure of Joseph McGuirl last year. As reported by RNAi News, McGuirl left UMMS after overseeing an RNAi licensing deal with CytRx that has become the source of a Massachusetts State Ethics Committee inquiry (see RNAi News, 5/21/2004).
Ittelson was formerly the director of the intellectual property office for the Whitehead Institute for Biomedical Research and the Massachusetts Institute of Technology, said McCooe & Associates. Prior to this, Ittelson was with consultancy firm The Mercury Group.
Cellectricon said this week that Axel Broms has been named as the Swedish company’s new chairman.
Patrick Lu, executive vice president of genomics and drug discovery at Intradigm, is scheduled to present at the Strategic Research Institute’s BioAsia Licensing and Deal Making Summit in August.
Lu’s presentation will focus on building strategic alliances with Chinese biopharmaceutical firms.